Abstract
Purpose
The aim of this study was to compare the safety and short-term efficacy of transcatheter arterial chemoembolization (TACE) using cisplatin-Lipiodol suspension (CP/Lp) with that using epirubicin-Lipiodol emulsion (EP/Lp) in patients with recurrent hepatocellular carcinoma (HCC).
Materials and methods
A total of 28 HCC patients were enrolled prospectively and assigned to the CP/Lp group or EP/Lp group. Adverse effects related to TACE were graded; and the treatment effect (TE) on HCC nodules at 3 months and overall tumor response at 6 months were assessed as the endpoint.
Results
No significant difference was observed between the groups regarding the frequency of adverse effects of grade 3 or less. The TE rates for 100% necrosis plus >50% necrosis in 62 HCC nodules in the CP/Lp group and 75 HCC nodules in the EP/Lp group were 72.6% and 66.7%, respectively (P = 0.894). Overall tumor response revealed that six patients (50.0%) in the CP/Lp group and six patients (37.5%) in the EP/Lp group had a partial response plus a complete response, with no significant difference (P = 0.615). TACE-free control curves for both groups revealed no significant difference (P = 0.513).
Conclusion
No significant difference was found with regard to adverse effects, the treatment effect on HCC nodules, or overall tumor response between the CP/Lp and EP/Lp groups.
Similar content being viewed by others
References
Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002;359:1734–1739.
Liang TJ, Jeffers IJ, Reddy KR, Medina M, Parkeret IT, Cheinquer H, et al. Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 1993;18:1326–1333.
Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–472.
Yamada R, Sato M, Kawabata M, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983;148:397–401.
Nishimine K, Uchida H, Matsuo N, Sakaguchi H, Hirohashi S, Nishimura Y, et al. Segmental transarterial chemoembolisation with Lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma; follow-up CT and therapeutic results. Cancer Chemother Pharmacol 1994;33:60–68.
Kawai S, Tani M, Okamura J, Ogawa M, Ohashi Y, Monden M, et al. Prospective and randomized trial of Lipiodol-transcatheter arterial chemoembolisation for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study)—The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol 1997;24(S6):38–45.
Bronowicki JP, Vetter D, Dumas F, Boudjema K, Bader R, Weiss AM, et al. Transcatheter oily embolisation for hepatocellular carcinoma: a 4-year study of 127 French patients. Cancer 1994;74:16–24.
Sasaki Y, Imaoka S, Kasugai H, Fujita M, Kawamoto S, Ishiguro S, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987;60:1194–1203.
Takayasu K, Muramatsu Y, Maeda T, Iwata R, Fukuoka H, Moriyama N, et al. Targeted transarterial oily chemoembolisation for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol 2001;176:681–688.
Kasugai H, Kojima J, Tatsuta M, Okuda S, Sasaki Y, Imaoka S, et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989;97:965–971.
Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T, et al. Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 1983;19:1053–1065.
Ono Y, Yoshimasu T, Ashikaga R, Inoue M, Shindou H, Fuji K, et al. Long-term results of Lipiodol-transcatheter arterial chemoembolisation with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 2000;23:564–568.
Sato M, Yamada R, Uchida B, Hedgepeth P, Rosch J. Effects of hepatic artery embolization with Lipiodol and gelatin sponge particles on normal swine liver. Cardiovasc Intervent Radiol 1993;16:348–354.
Sahara S, Tanihata H, Sato M, Kawai N, Takasaka I, Minamiguchi H, et al. Effects of hepatic artery chemoembolization using cisplatin-Lipiodol suspension with gelatin sponge particles on swine liver. J Vasc Interv Radiol 2009;20:1359–1364.
Cooley ME, Davis L, Abrahm J. Cisplatin: a clinical review. Part II. Nursing assessment and management of side effects of cisplatin. Cancer Nurs 1994;17:283–293.
Maeda S, Shibata J, Fujiyama S, Tanaka M, Noumaru S, Sato K, et al. Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for heaptocellular carcinoma. Hepatogastroenterology 2003;50:809–813.
Uyama N, Hatano N, Maetani Y, Isoda H, Shibata T, Taura K, et al. Efficacy and toxicity of transcatheter arterial chemoembolisation with cisplatin suspended in Lipiodol for unresectable hepatocellular carcinoma. Jpn J Cancer Chemother 2008;35:775–780.
Masuda M. Evaluation of basic and clinical study on effect of anticancer drugs of Lipiodol in chemoembolization on liver tissue. J Wakayama Med Soc 2002;53:185–192.
Kamada K, Nakanishi T, Kitamoto M, Aikata H, Kawakami Y, Imaoka S, et al. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin Lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 2001;12:847–854.
Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH, et al. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma: a randomized controlled study. Cancer 1994;74:2449–2453.
Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 5th edition, revised version. Tokyo: Kanehara; 2009 p. 29–34.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Sahara, S., Kawai, N., Sato, M. et al. Prospective comparison of transcatheter arterial chemoembolization with Lipiodol-epirubicin and Lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma. Jpn J Radiol 28, 362–368 (2010). https://doi.org/10.1007/s11604-010-0436-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11604-010-0436-y